Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02893293 · ClinicalTrials.gov registry record · Phase 4
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
A Phase 4 study of Osteonecrosis, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02893293: Completed Phase 4 study of Osteonecrosis, sponsored by Stanford University.
NCT02893293 is a Phase 4 study of Osteonecrosis that has completed, run by Stanford University. The registered enrollment target is 14 participants, below the 2,921-participant average among 7 other Osteonecrosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02893293, a Phase 4 study of Osteonecrosis, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the project is to evaluate osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI.
Primary Outcome
SNR is a measurement that compares the strength of a signal to the level of background noise. It is often expressed in decibels (dB) and is calculated by dividing the signal power by the noise power. A ratio greater than 1:1 indicates that there is more signal than noise. First, for each lesion the MR signal intensity (SI) of the lesion and the SI of the background (= noise in the image) was measured, then the SI of the lesion was divided by the SI of the noise to obtain the signal to noise rat
Conditions Studied
Interventions
- DRUG Ferumoxytol-enhanced magnetic resonance imaging
- DEVICE Magentic Resonance Imaging
Study Locations (1)
California
- Lucile Packard Children's Hospital - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-05 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 4 |
What the finished NCT02893293 record still lists
NCT02893293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 2,921-participant average among 7 other Osteonecrosis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Osteonecrosis appearing as the primary indexed condition, and to 2 interventions - of which Ferumoxytol-enhanced magnetic resonance imaging is the first listed.
NCT02893293 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02893293 about?
NCT02893293 is a clinical study titled "Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI". The goal of the project is to evaluate osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI.
What is the current status of trial NCT02893293?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2015-05. Estimated completion is 2023-10-31.
What conditions does trial NCT02893293 study?
This clinical trial studies the following conditions: Osteonecrosis.
What interventions are being tested in trial NCT02893293?
The interventions under investigation include: Ferumoxytol-enhanced magnetic resonance imaging (DRUG), Magentic Resonance Imaging (DEVICE).
Who is sponsoring clinical trial NCT02893293?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02893293 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteonecrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
RECRUITING · Phase 2
-
Early Feasibility Study of Cartilage Defect Repair
RECRUITING · NA
-
Exactech Shoulder Post Market Clinical Follow-up Study
RECRUITING
-
Sickle Cell Disease (SCD) Bone Pain Study
ACTIVE NOT RECRUITING · NA
-
The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head
ACTIVE NOT RECRUITING
-
Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia